Winsford medical manufacturer AMS delivers year of profit growth
Surgical and wound care product manufacturer Advanced Medical Solutions Group plc (AMS) achieved profit and revenue growth in 2015 despite “challenging currency conditions”.
In the 12 months to December 31, Cheshire-based AMS’ profit before tax rose year on year by 12% to reach £17m, while its adjusted operating profit likewise by grew 12%, at £17.4m.
AMS’ revenue also increased last year, rising by 9% at £68.6m, which is an increase of more than £5m.
Commenting on the results, Chris Meredith, the chief executive officer at AMS, said 2015 represented “another strong year of growth” for the Winsford firm.
He said: “[We] are pleased to report that all of our business units are performing well despite some challenging currency conditions.
“The growth in the US has been markedly strong for AMS where the performance and range of our LiquiBand tissue adhesives, in particular, is driving market share gains.
Mr Meredith continued: “We have also been pleased with the number of new product approvals we have achieved this year, demonstrating the continuing success of our innovation and we are confident that, with our strong R&D pipeline, we will continue to deliver growth.”
Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →
Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.
The true value of HR in an AI-driven working world
What new business rates guidance means for pubs
Business success starts with people investment
It's time to confront the digital poverty crisis
Why a business exit is no longer all or nothing
Culture is the foundation for sustainable growth
Business must help young people take root in work
Purposeful procurement for long-term growth
Time to rethink outdated views on apprenticeships
The scale-ups rocketing through our fast world
Care about the experience, not just the outcome
The rise of an alternative investor model